These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36578488)

  • 21. A promising self-nanoemulsifying adjuvant with plant-derived saponin D boosts immune response and exerts an anti-tumor effect.
    Luo X; Song Z; Zeng X; Ye Y; Zheng H; Cai D; Yuan Q; Li H; Tong Y; Lu D; Liu Y; Zeng H; Yang Y; Sun H; Zou Q
    Front Immunol; 2023; 14():1154836. PubMed ID: 37415983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pneumococcal serotype-specific IgG and opsonophagocytic activity in young Japanese patients with asplenia.
    Takeshita K; Takeuchi N; Takahashi Y; Fukasawa C; Hishiki H; Hoshino T; Ishiwada N; Shimojo N
    Hum Vaccin Immunother; 2021 Oct; 17(10):3687-3691. PubMed ID: 34213395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies.
    Chu RS; McCool T; Greenspan NS; Schreiber JR; Harding CV
    Infect Immun; 2000 Mar; 68(3):1450-6. PubMed ID: 10678959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acylated and deacylated quillaja saponin-21 adjuvants have opposite roles when utilized for immunization of C57BL/6 mice model with MOG
    Heidari AR; Boroumand-Noughabi S; Nosratabadi R; Lavi Arab F; Tabasi N; Rastin M; Mahmoudi M
    Mult Scler Relat Disord; 2019 Apr; 29():68-82. PubMed ID: 30685444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of C28 Oligosaccharide on Adjuvant Activity of QS-7 Analogues.
    Škalamera Đ; Kim H; Zhang P; Michalek SM; Wang P
    J Org Chem; 2020 Dec; 85(24):15837-15848. PubMed ID: 32463234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany.
    Kieninger DM; Kueper K; Steul K; Juergens C; Ahlers N; Baker S; Jansen KU; Devlin C; Gruber WC; Emini EA; Scott DA;
    Vaccine; 2010 Jun; 28(25):4192-203. PubMed ID: 20417262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IgG levels against 13-valent pneumococcal conjugate vaccine serotypes in non pneumococcal conjugate vaccine immunized healthy Japanese and intravenous immunoglobulin preparations.
    Takahashi Y; Ishiwada N; Hishiki H; Tanaka J; Akeda Y; Shimojo N; Oishi K; Kohno Y
    J Infect Chemother; 2014 Dec; 20(12):794-8. PubMed ID: 25242584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a minimal saponin vaccine adjuvant based on QS-21.
    Fernández-Tejada A; Chea EK; George C; Pillarsetty N; Gardner JR; Livingston PO; Ragupathi G; Lewis JS; Tan DS; Gin DY
    Nat Chem; 2014 Jul; 6(7):635-43. PubMed ID: 24950335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploiting structure-activity relationships of QS-21 in the design and synthesis of streamlined saponin vaccine adjuvants.
    Ghirardello M; Ruiz-de-Angulo A; Sacristan N; Barriales D; Jiménez-Barbero J; Poveda A; Corzana F; Anguita J; Fernández-Tejada A
    Chem Commun (Camb); 2020 Jan; 56(5):719-722. PubMed ID: 31833496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine.
    Quinet B; Laudat F; Gurtman A; Patterson S; Sidhu M; Gruber WC; Scott DA
    Pediatr Infect Dis J; 2014 Oct; 33(10):1065-76. PubMed ID: 25093973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.
    Diez-Domingo J; Gurtman A; Bernaola E; Gimenez-Sanchez F; Martinon-Torres F; Pineda-Solas V; Delgado A; Infante-Marquez P; Liang JZ; Giardina PC; Gruber WC; Emini EA; Scott DA
    Vaccine; 2013 Nov; 31(46):5486-94. PubMed ID: 24004465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults.
    Stacey HL; Rosen J; Peterson JT; Williams-Diaz A; Gakhar V; Sterling TM; Acosta CJ; Nolan KM; Li J; Pedley A; Benner P; Abeygunawardana C; Kosinski M; Smith WJ; Pujar H; Musey LK
    Hum Vaccin Immunother; 2019; 15(3):530-539. PubMed ID: 30648919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. QS-21 Adjuvant: Laboratory-Scale Purification Method and Formulation Into Liposomes.
    Brunner L; Barnier-Quer C; Collin N
    Methods Mol Biol; 2017; 1494():73-86. PubMed ID: 27718186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural and Synthetic Saponins as Vaccine Adjuvants.
    Wang P
    Vaccines (Basel); 2021 Mar; 9(3):. PubMed ID: 33807582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED).
    Lupinacci R; Rupp R; Wittawatmongkol O; Jones J; Quinones J; Ulukol B; Dagan R; Richmond P; Stek JE; Romero L; Koseoglu S; Tamms G; McFetridge R; Li J; Cheon K; Musey L; Banniettis N; Bickham K;
    Vaccine; 2023 Jan; 41(5):1142-1152. PubMed ID: 36621410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia.
    Urbancikova I; Prymula R; Goldblatt D; Roalfe L; Prymulova K; Kosina P
    Vaccine; 2017 Sep; 35(38):5186-5193. PubMed ID: 28797727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and Evaluation of QS-7-Based Vaccine Adjuvants.
    Wang P; Škalamera Đ; Sui X; Zhang P; Michalek SM
    ACS Infect Dis; 2019 Jun; 5(6):974-981. PubMed ID: 30920199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant activities of saponins from the root of Polygala senega L.
    Katselis GS; Estrada A; Gorecki DK; Barl B
    Can J Physiol Pharmacol; 2007 Nov; 85(11):1184-94. PubMed ID: 18066120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advances in saponin-based adjuvants.
    Sun HX; Xie Y; Ye YP
    Vaccine; 2009 Mar; 27(12):1787-96. PubMed ID: 19208455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post hoc analysis of a randomized double-blind trial of the correlation of functional and binding antibody responses elicited by 13-valent and 7-valent pneumococcal conjugate vaccines and association with nasopharyngeal colonization.
    Juergens C; Patterson S; Trammel J; Greenberg D; Givon-Lavi N; Cooper D; Gurtman A; Gruber WC; Scott DA; Dagan R
    Clin Vaccine Immunol; 2014 Sep; 21(9):1277-81. PubMed ID: 24990907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.